Discover the full directors' dealings record of Magellan Health INC, a publicly traded company based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Magellan Health INC has published 50 insider filings. The latest transaction was reported on 4 January 2022 — Disposition. Among the most active insiders: Feld Peter A. The full history is openly available.
0 of 0 declarations
Magellan Health Inc. (ticker: MGLN) was a United States-listed healthcare services company focused on managed care and specialty healthcare administration. In its public filings, Magellan described itself as operating in some of the fastest-growing and most complex parts of healthcare, including special populations, pharmacy benefits management, and other specialty healthcare solutions. Its customer base included health plans, other managed care organizations, employers, labor unions, military and government agencies, and third-party administrators. The company’s executive offices were in Scottsdale, Arizona, United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/19411/000155837017000981/mgln-20161231x10k.htm?utm_source=openai)) Founded in 1969, Magellan Health underwent several strategic reinventions over time. It originated from Charter Medical and later evolved from a behavioral-health-focused business into a broader healthcare management platform. Through acquisitions and internal development, Magellan expanded capabilities in behavioral health, pharmacy benefit management, and specialized care management. The company’s long history reflects a shift from a traditional healthcare operator toward a more specialized services model built around clinical expertise, analytics, and technology-enabled care coordination. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Magellan_Health?utm_source=openai)) From a business-model perspective, Magellan was a niche specialist rather than a broad-based health insurer. Its competitive proposition centered on delivering tailored solutions for complex patient populations and fragmented care environments. Key service lines included behavioral health management, pharmacy benefit services, and specialized healthcare programs designed to improve outcomes while lowering the total cost of care. That made Magellan relevant in segments where deep clinical management, data analytics, and operational execution can matter more than scale alone. ([sec.gov](https://www.sec.gov/Archives/edgar/data/19411/000155837017000981/mgln-20161231x10k.htm?utm_source=openai)) For investors, it is crucial to note that MGLN is no longer an independent publicly traded equity. Centene completed its acquisition of Magellan Health, and Magellan common stock ceased trading before the opening of trading on January 4, 2022. As a result, references to Magellan Health in a stock-market context are now historical and should be read in the context of Centene’s acquisition rather than as a currently listed standalone NYSE/NASDAQ security. ([magellanhealth.com](https://www.magellanhealth.com/documents/2024/03/01-04-2022_pr.pdf/?utm_source=openai)) The most important recent corporate event was therefore the Centene acquisition, which effectively ended Magellan Health’s life as a standalone listed company. Prior filings also show divestitures such as the sale of Magellan Complete Care in 2020, indicating a period of portfolio reshaping before the final transaction. For equity research purposes, Magellan is best understood as a former U.S. specialty healthcare manager with a focused competitive niche, rather than an active independent listed issuer today. ([sec.gov](https://www.sec.gov/Archives/edgar/data/19411/000155837021002031/mgln-20201231x10k.htm?utm_source=openai))